The UK financial markets regulator has finalised rules strengthening the duty of asset managers to act in the best interests of investors in their funds.
The rules are the first that the Financial Conduct Authority (FCA) has adopted following its landmark asset management market study. The study, published last year, found weak price competition among asset managers and led it to refer the investment consultant sector for a competition investigation.
The regulator dropped the term “value for money” from the rules requiring fund managers to justify to investors the charges they take from funds, following a consultation.
However, requirements published on April 5 today stated that fund charges should be assessed annually in the context of the overall value delivered.
The supervisor will also make it “easier for firms to switch investors to cheaper versions of the same fund,” Andrew Strange, a director at PricewaterhouseCoopers, said in an email. It’s an example “of the regulator helping firms deliver value,” he said.
The supervisor estimated in 2016 that about £109 billion (US$153 billion) was tied up in active funds that closely mirror market performance but charge higher fees than passive products. Some firms charged fees like active managers but operated like lower-cost passive funds, the FCA said last month. The firms paid £34 million (US$47.6 million) in compensation to investors in the funds.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas